Yasmeen Rahimi, Ph.D.

Sr. Research Analyst
Sector Expertise
Additional Expertise
Yasmeen Rahimi is a managing director and senior research analyst at Piper Sandler covering biotechnology. Prior to joining Piper Sandler in July 2020, Rahimi was a senior research analyst and co-head of biotechnology equity research team at ROTH Capital Partners. Before that, she worked as an equity research associate at H.C. Wainwright & Co. and Guggenheim Securities. Prior to making the transition to Wall Street, Rahimi was a research scientist at Shire Pharmaceuticals where she developed biomarker strategies for a number of rare disease programs; she has extensive expertise in liver metabolism. Rahimi trained as a postdoctoral fellow at Yale University in the laboratory of Gerald Shulman after completing her Ph.D. from Indiana University School of Medicine. In addition, she has a M.S. in bioanalytical chemistry from Purdue University and a joint B.A. in German and chemistry from Butler University.

Universe Coverage

ALTAltimmune, Inc.
IMUXImmunic, Inc.
ICPTIntercept Pharmaceuticals, Inc.
MDGLMadrigal Pharmaceuticals, Inc.
CBAYCymaBay Therapeutics Inc.
LUMOLumos Pharma, Inc.
ARCTArcturus Therapeutics Holdings, Inc.
SVRASavara, Inc.
SAGESage Therapeutics, Inc.
PRAXPraxis Precision Medicines, Inc.
DSGNDesign Therapeutics, Inc.
RPHMReneo Pharmaceuticals, Inc.
ALGSAligos Therapeutics, Inc.
TNYATenaya Therapeutics, Inc.
GOSSGossamer Bio
CYTKCytokinetics, Incorporated
VTYXVentyx Biosciences, Inc.
LXRXLexicon Pharmaceuticals, Inc.
VRNAVerona Pharma Plc
AKUSAkouos, Inc.
PLRXPliant Therapeutics, Inc.
PRTAProthena Corporation plc
ALLKAllakos, Inc.
IMVTImmunovant, Inc.
LIFEaTyr Pharma, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
GPCRStructure Therapeutics, Inc.
SGMTSagimet Biosciences, Inc.